会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 65. 发明申请
    • Diagnosis and treatment of breast cancer
    • 诊断和治疗乳腺癌
    • US20060154267A1
    • 2006-07-13
    • US11089097
    • 2005-03-24
    • Xiao-Jun MaMark ErlanderDennis SgroiEdward Enright
    • Xiao-Jun MaMark ErlanderDennis SgroiEdward Enright
    • G06Q10/00C12Q1/68G06Q50/00
    • C12Q1/6886C12Q2600/106C12Q2600/154C12Q2600/158G06Q50/22
    • Methods and compositions are provided for the identification of expression signatures in ER+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to treatment with tamoxifen or another antiestrogen agent against breast cancer The signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with breast cancer with tamoxifen or another antiestrogen agent against breast cancer. Additional methods and compositions are provided for predicting responsiveness to tamoxifen or another antiestrogen agent against breast cancer in cases of breast cancer by use of multiple biomarkers. Two biomarkers display increased expression correlated with tamoxifen response while two other biomarkers display decreased expression correlated with tamoxifen response.
    • 提供了方法和组合物用于鉴定ER +乳腺癌病例中的表达标志,其中签名与反应性或缺乏相关,与他莫昔芬或另一种针对乳腺癌的抗雌激素剂的治疗相关。基于参考乳腺的抽样来鉴定签名谱 来自乳腺癌独立病例的组织样本,并提供可靠的一组分子标准,用于预测使用他莫昔芬或其他抗雌激素剂对乳腺癌进行乳腺癌治疗的受试者的疗效。 提供了另外的方法和组合物,用于通过使用多种生物标志物来预测在乳腺癌病例中对他莫昔芬或另一种抗雌激素剂对乳腺癌的反应性。 两种生物标志物显示与他莫昔芬反应相关的增加的表达,而另外两种生物标志物显示与他莫昔芬反应相关的降低的表达。
    • 66. 发明申请
    • Predicting breast cancer treatment outcome
    • 预测乳腺癌治疗结果
    • US20050239083A1
    • 2005-10-27
    • US10773761
    • 2004-02-06
    • Mark ErlanderXiao-Jun MaDennis Sgroi
    • Mark ErlanderXiao-Jun MaDennis Sgroi
    • C12M1/34C12Q1/68
    • C12Q1/6886C12Q2600/106C12Q2600/154C12Q2600/158
    • Methods and compositions are provided for the identification of expression signatures in ER+ breast cancer cases, where the signatures correlate with responsiveness, or lack thereof, to treatment with tamoxifen or another antiestrogen agent against breast cancer The signature profiles are identified based upon sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for predicting the efficacy of treating a subject with breast cancer with tamoxifen or another antiestrogen agent against breast cancer. Additional methods and compositions are provided for predicting responsiveness to tamoxifen or another antiestrogen agent against breast cancer in cases of breast cancer by use of three biomarkers. Two biomarkers display increased expression correlated with tamoxifen response while the third biomarker displays decreased expression correlated with tamoxifen response.
    • 提供了方法和组合物用于鉴定ER +乳腺癌病例中的表达标志,其中签名与反应性或缺乏相关,与他莫昔芬或另一种针对乳腺癌的抗雌激素剂的治疗相关。基于参考乳腺的抽样来鉴定签名谱 来自乳腺癌独立病例的组织样本,并提供可靠的一组分子标准,用于预测使用他莫昔芬或其他抗雌激素剂对乳腺癌进行乳腺癌治疗的受试者的疗效。 提供了另外的方法和组合物,用于通过使用三种生物标志物来预测在乳腺癌病例中对他莫昔芬或另一种针对乳腺癌的抗雌激素剂的反应性。 两种生物标志物显示与他莫昔芬反应相关的增加的表达,而第三种生物标志物显示与他莫昔芬反应相关的降低的表达。
    • 68. 发明申请
    • RNASCOPE® HPV ASSAY FOR DETERMINING HPV STATUS IN HEAD AND NECK CANCERS AND CERVICAL LESIONS
    • 用于确定头颈部和颈部癌症和宫颈癌HPV状态的RNASCOPE®HPV测定
    • US20120214152A1
    • 2012-08-23
    • US13359706
    • 2012-01-27
    • Xiao-Jun MaJohn FlanaganYuling Luo
    • Xiao-Jun MaJohn FlanaganYuling Luo
    • C12Q1/70C12M1/34
    • C12Q1/708C12Q1/6841C12Q1/6886C12Q2600/112C12Q2600/118
    • The present invention provides a method and a kit for determining whether a head and neck cancer is HPV-related. In one embodiment, an RNAscope® HPV assay was designed to detect the presence of E6/E7 mRNA of certain high-risk HPV subtypes related to head and neck cancer. The present invention also provides a method and a kit for determining whether a cervical lesion is a benign lesion or a cervical intraepithethial neoplasm lesion. The present invention further provides a method for determining the progression of cervical intraepithethial neoplasm based on the spatial pattern and levels of the E6/E7 mRNA of certain high-risk HPV subtypes. The present invention also provides a method for determining the risk of developing cervical cancer in a human diagnosed with cervical intraepithethial neoplasm based on presence and absence of the certain subgroups of high-risk HPV subtypes.
    • 本发明提供了一种用于确定头颈癌是否与HPV相关的方法和试剂盒。 在一个实施方案中,设计了RNA检测HPV检测来检测某些与头颈癌相关的高危HPV亚型的E6 / E7 mRNA的存在。 本发明还提供了一种用于确定子宫颈病变是否是良性病变或子宫颈上皮内肿瘤病变的方法和试剂盒。 本发明还提供了一种基于某些高风险HPV亚型的E6 / E7 mRNA的空间格局和水平来确定子宫颈上皮内肿瘤进展的方法。 本发明还提供了一种基于存在和不存在某些亚型的高风险HPV亚型的方法来确定诊断为宫颈上皮内瘤的人的宫颈癌发生风险的方法。
    • 69. 发明申请
    • ADAPTIVE TRIGGERING SET FOR RELAXED DETERMINISTIC BACK-OFF METHOD
    • 自适应触发设置用于放松确定的后退方法
    • US20120063307A1
    • 2012-03-15
    • US13320603
    • 2010-05-18
    • Yong HeXiao-Jun MaJun Li
    • Yong HeXiao-Jun MaJun Li
    • H04L12/26
    • H04W74/0841
    • A method and system are described including retrieving a sparseness indication, retrieving an indication of a number of failed transmissions, comparing the sparseness indication to an optimal sparseness, comparing the number of failed transmissions to a first threshold, adjusting a size of a set of triggering events responsive to both the first and the second comparison, comparing a data buffer push rate to a data buffer arrival rate, further adjusting the size of the triggering set responsive to the third comparison, determining system fairness, comparing the size of the triggering set to a second threshold and further adjusting the size of the triggering set responsive to one of the determination and a combination of the determination and the fourth comparison.
    • 描述了一种方法和系统,包括检索稀疏指示,检索多个故障传输的指示,将稀疏指示与最佳稀疏比较,将失败传输的数量与第一阈值进行比较,调整一组触发的大小 响应于第一和第二比较的事件,将数据缓冲器推送速率与数据缓冲器到达速率进行比较,响应于第三比较进一步调整触发集合的大小,确定系统公平性,将触发集合的大小与 第二阈值,并且响应于所述确定中的一个和所述确定和所述第四比较的组合进一步调整所述触发集合的大小。
    • 70. 发明授权
    • Method and apparatus for media access in contention-based networks
    • 用于基于竞争的网络中的媒体访问的方法和装置
    • US07944940B2
    • 2011-05-17
    • US12452161
    • 2007-06-22
    • Xiao-Jun MaYong HeZhigang ZhangHuanqiang ZhangJun LiCharles Chunaming Wang
    • Xiao-Jun MaYong HeZhigang ZhangHuanqiang ZhangJun LiCharles Chunaming Wang
    • H04L12/413
    • H04W74/085
    • A method and apparatus are described for gaining access to a communication medium in a contention-based network, including determining a slot count based on a number of stations in the contention-based network, adjusting the slot count, initiating a frame transmission when the slot count reaches a predetermined value and wherein said number of stations and an address queue are adjusted to reflect a priority. Further, a method and apparatus are described for gaining access to a communication medium in a contention-based network, including receiving a slot count based on a number of stations in the contention-based network, adjusting the slot count, initiating a frame transmission when the slot count reaches a predetermined value and wherein said number of stations and an address queue are adjusted to reflect a priority.
    • 描述了一种用于在基于竞争的网络中获取对通信介质的访问的方法和装置,包括基于在基于竞争的网络中的站数量来确定时隙计数,调整时隙计数,当时隙发起帧传输 计数达到预定值,并且其中调整所述站数和地址队列以反映优先级。 此外,描述了一种用于在基于竞争的网络中获取对通信介质的访问的方法和装置,包括基于在基于竞争的网络中的站点数目接收时隙计数,调整时隙计数,启动帧传输, 时隙计数达到预定值,并且其中所述站数和地址队列被调整以反映优先级。